serum pcsk9  (BioVendor Instruments)

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: Design and systematic evaluation of novel chemical modification patterns enable the identification of a potent siRNA targeting PCSK9

doi: 10.1016/j.omtm.2025.101609

Figure Lengend Snippet: qPCR-measured inhibitory rate of modified PC sequence on target PCSK9 mRNA in Hep3B cells The modification patterns involved in studying the preferences of residues at certain positions are shown (A). The inhibitory rates of modified siRNAs on target PCSK9 mRNA were measured in Hep3B cells (B). siRNAs were transfected into Hep3B cells at a concentration of 50 pM, and the PCSK9 mRNA levels in cells after 48 h of transfection were measured by qPCR as described. The inhibitory rate of the PC without GalNAc is shown as a black bar on the left. Means ± SD are shown. Differences were analyzed using one-way ANOVA. Multiple comparisons were conducted between the PC group and other groups using GraphPad Prism, and p values were adjusted using Dunnett’s method. siRNAs with significantly higher inhibition efficacies are labeled on the graph. ∗ p < 0.05, ∗∗ p < 0.01.

Article Snippet: Serum PCSK9 levels were determined using ELISA (Proteintech, KE00181).

Techniques: Modification, Sequencing, Transfection, Concentration Assay, Inhibition, Labeling

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: Design and systematic evaluation of novel chemical modification patterns enable the identification of a potent siRNA targeting PCSK9

doi: 10.1016/j.omtm.2025.101609

Figure Lengend Snippet: Inhibition efficiency of YK1597-DV29PG5 on PCSK9, LDL-C, and TC in cynomolgus monkeys Inhibitory rates of YK1597-DV29PG5 at different doses (3, 6, and 10 mg/kg s.c.) on target protein LDL-C and TC in cynomolgus monkeys ( n = 6) were measured with ELISA after introduction for a period of 84 days, with group means ± SD shown. Expression of the target protein PCSK9 was measured over a period of 84 days (A), and the relevant percentages of PCSK9 protein expression during that period are shown (B). LDL-C levels are shown in (C and D), while the levels of TC are shown in (E and F).

Article Snippet: Serum PCSK9 levels were determined using ELISA (Proteintech, KE00181).

Techniques: Inhibition, Enzyme-linked Immunosorbent Assay, Expressing

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: Design and systematic evaluation of novel chemical modification patterns enable the identification of a potent siRNA targeting PCSK9

doi: 10.1016/j.omtm.2025.101609

Figure Lengend Snippet: Inhibition of PCSK9 mRNA by the newly designed siRNAs with ESC pattern modification Six siRNAs were transfected into Hep3B cells at 50 pM using Lipofectamine RNAiMAX to determine their effects on the inhibition of PCSK9 . The sequence of the PC was selected and modified with the ESC pattern and used as the PC. Cells were incubated in a 37°C, 5% CO 2 incubator for 48 h before harvesting. The levels of PCSK9 expression were then measured using qPCR. Means ± SD are shown. One-way ANOVA and multiple comparisons were carried out between the PC-ESC group and other groups using GraphPad Prism, and p values were adjusted using Dunnett’s method. siRNAs with significantly higher inhibition efficacy are labeled on the graph. ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001.

Article Snippet: Serum PCSK9 levels were determined using ELISA (Proteintech, KE00181).

Techniques: Inhibition, Modification, Transfection, Sequencing, Incubation, Expressing, Labeling

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: Design and systematic evaluation of novel chemical modification patterns enable the identification of a potent siRNA targeting PCSK9

doi: 10.1016/j.omtm.2025.101609

Figure Lengend Snippet: qPCR-measured inhibitory rate of siRNAs with new modification patterns on PCSK9 mRNA in Hep3B cells and the inhibition of modified siRNAs on serum PCSK9 and LDL-C in transgenic mice (A) The inhibitory rates of modified siRNAs on target PCSK9 mRNA were measured in Hep3B cells. siRNAs were transfected into Hep3B cells at a concentration of 50 pM using Lipofectamine RNAiMAX. Cells were then incubated in a 37°C, 5% CO 2 incubator for 48 h before harvesting, and the PCSK9 mRNA levels in cells after transfection were measured by qPCR as introduced. The inhibitory rate of PC without GalNAc is shown as a black bar on the left. Group means ± SD are shown. One-way ANOVA and multiple comparisons were conducted between the PC group and other groups using GraphPad Prism. For sequences based on YK1588 and YK1598, multiple comparisons were also performed between ESC groups and other modification groups. p values were adjusted using Dunnett’s method. siRNAs with significantly higher inhibition efficacy are labeled on the graph. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001, ∗∗∗∗ p < 0.0001. (B–D) In vivo inhibition efficiency of newly designed siRNAs with our modification patterns (dose: 6 mg/kg) was measured using hPCSK9 transgenic mice (B6-hPCSK9, n = 5). Group means ± SD are shown. Target protein expression level and LDL-C level were measured using ELISA and a clinical chemistry analyzer, respectively, as described. The inhibitory rate of the PC is shown to compare the inhibition efficiencies of newly designed siRNAs. The serum hPCSK9 inhibitory rates of modified siRNAs based on basic sequences 1596, 1597, and 1599 are shown in (B–D), respectively.

Article Snippet: Serum PCSK9 levels were determined using ELISA (Proteintech, KE00181).

Techniques: Modification, Inhibition, Transgenic Assay, Transfection, Concentration Assay, Incubation, Labeling, In Vivo, Expressing, Enzyme-linked Immunosorbent Assay

Journal: Molecular Therapy. Methods & Clinical Development

Article Title: Design and systematic evaluation of novel chemical modification patterns enable the identification of a potent siRNA targeting PCSK9

doi: 10.1016/j.omtm.2025.101609

Figure Lengend Snippet: Inhibition of modified siRNAs on PCSK9 in transgenic mice and cynomolgus monkeys (A) In vivo inhibition efficiencies of YK1597-DV27G and YK1597-DV29G (light blue and purple triangles, respectively) were measured together with siRNAs possessing the same sequences but with a 5′-VP at the 5′-end of AS strands (YK1597-DV27PG and YK1597-DV29PG shown as dark blue squares and green triangles, respectively). Group means ± SD are shown. (B) Efficacy evaluation at a dose of 2 mg/kg using hPCSK9 transgenic mice (B6-hPCSK9, n = 6). Group means ± SD are shown, and the inhibition of inclisiran is shown as the control (red dots). The expression level of the target protein PCSK9 was measured by ELISA as introduced, and the serum hPCSK9 inhibitory rate is shown (A). The inhibition of PCSK9 mRNA in the liver of transgenic mice was measured at the end of the experiment (day 35) using qPCR. Differences in serum PCSK9 between PC and other groups were analyzed using two-way ANOVA, and differences in liver mRNA levels between PC and other groups were analyzed using one-way ANOVA. Multiple comparisons were then performed between the PC group and other groups. Groups with significantly higher inhibition efficacies are labeled on the graph. p values were corrected using Dunnett’s method. ∗ p < 0.05, ∗∗ p < 0.01, ∗∗∗ p < 0.001. (C) Serum PCSK9 and LDL-C inhibitory rates of YK1597-DV27PG and YK1597-DV29PG (dark blue and green triangles, respectively) were also measured in cynomolgus monkeys dosed at 6 mg/mL (male, n = 2). Group means ± SD are shown.

Article Snippet: Serum PCSK9 levels were determined using ELISA (Proteintech, KE00181).

Techniques: Inhibition, Modification, Transgenic Assay, In Vivo, Control, Expressing, Enzyme-linked Immunosorbent Assay, Labeling

Journal: Turkish Journal of Biochemistry

Article Title: Evaluation of adropin indices and PCSK9 in non-diabetic men with severe obstructive sleep apnea

doi: 10.1515/tjb-2023-0283

Figure Lengend Snippet: Figure 1: Comparing adropin indices and PCSK9 levels among the groups using box-plot graphics. (A) Adropin/BMI. (B) Adropin/WC. (C) Adropin/NC. (D) PCSK9 levels. BMI, body mass index; WC, waist circumference; NC, neck circumference; PCSK9, proprotein convertase subtilisin/kexin type 9; OSA, obstructive sleep apnea; ns, non-significant. Pairwise comparisons were conducted using Bonferroni correction for the Kruskal–Wallis test, accepting a significance level of 0.017 for the adjusted p-value.

Article Snippet: Serum adropin (Catalog number: E-EL-H5307; Elabscience Biotechnology Co., Ltd, Houston, Texas, USA) and serum PCSK9 (Catalog number: RD191473200R; Biovendor R&D Products, Brno, Czech Republic) concentrations were evaluated via ELISA (Synergy HT, Biotek Instruments, Inc., USA) device.

Techniques: